Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

NCT05120271 is registered in ClinicalTrials.gov with Sotio Biotech Inc. as lead sponsor.

NCT NCT05120271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05120271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Lead sponsor
Sotio Biotech Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 26, 2022
Completion date
December 31, 2042
Enrollment
7 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, merkel cell carcinoma, myxoid/round cell liposarcoma, squamous cell carcinoma of the lung